Kasenda, B
Ihorst, G
Schroers, R
Korfel, A
Schmidt-Wolf, I
Egerer, G
von Baumgarten, L
Röth, A
Bloehdorn, J
Möhle, R
Binder, M
Keller, U
Lamprecht, M
Pfreundschuh, M
Valk, E
Fricker, H
Schorb, E
Fritsch, K
Finke, J
Illerhaus, G
Article History
Received: 23 March 2017
Revised: 8 May 2017
Accepted: 15 May 2017
First Online: 31 May 2017
Competing interests
: AK discloses honoraria from PIQUR, Mundipharama and Riemser, research funding from Mundipharma and Riemser, and travel support from PIQUR, Mundipharama and Riemser. AR discloses consultancy activities for Novartis and Roche. ES discloses travel support from Amgen, Janssen and Baxter. GI discloses honoraria from Riemser, consultancies for Celgene, travel support from Roche, BMS and Roche. JF discloses travel support from Riemser and Medac. MB discloses honoraria from Hexal Biosimilars, Sanofi and MSD, consulting activities for BMS, Roche, Hexal Biosimilars, Takeda, and travel support by Takeda, Gilead and Hexal Biosimilars. RS discloses travel support from Celgene, Janssen and Sanofi. UK discloses stock ownership of Kite Pharmaceuticals, consulting activities for Roche, BMS; Janssen, MSD, Merck, Gilead and Takeda, being part of speaker’s bureau of Gilead and travel support by Roche, BMS and Takeda. The remaining authors declare no conflict of interest.